NCT05446233View on ClinicalTrials.gov

ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

January 2, 2023

Study Completion Date

January 2, 2023

Conditions
Healthy Male Subjects
Interventions
DRUG

[14C] Antaitavir Hasophate

100 mg suspension containing 200µCi of \[14C\] Antaitavir Hasophate

Trial Locations (1)

Unknown

Shanghai xuhui central hospital, Shanghai

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY